Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31257349 | 0.70 | GRM5 (0.41) | HRH4DYRK1AHPGDALDH1A1LMNA | |
| SCHEMBL15509076 | 0.70 | GRM5 (0.41) | HRH4DYRK1AHPGDALDH1A1LMNA | |
| SCHEMBL31221748 | 0.69 | MET (0.46) | HRH4DYRK1AALDH1A1 | |
| SCHEMBL1104630 | 0.69 | MET (0.46) | HRH4DYRK1AALDH1A1 | |
| SCHEMBL13137283 | 0.69 | DYRK1A (0.33) | DYRK1AALDH1A1 | |
| SCHEMBL8501962 | 0.69 | HRH4 (0.31) | HRH4DYRK1AALDH1A1 | |
| SCHEMBL19911443 | 0.68 | CHRNB2 (0.45) | DYRK1AHPGDALDH1A1LMNA | |
| SCHEMBL4282443 | 0.67 | KDM4E (0.32) | HRH4DYRK1AALDH1A1 | |
| SCHEMBL10238677 | 0.67 | PRPS1 (0.42) | DYRK1AHPGDALDH1A1 | |
| SCHEMBL7916582 | 0.67 | HRH4 (0.38) | HRH4DYRK1AHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254114-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254114-A1 | PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | HRH4 2984/4885DYRK1A 3684/4885HPGD 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.